In April, it was approved for use in Europe, the active ingredient Bempedoinsäure for the treatment of high cholesterol levels. In a new Review has now been checked, how big is the effect of the drug is used alone or in combination with other Cholesterol-lowering drugs from the group of statins. The results are published in the journal Yama.
Researchers at the Medical University of Łódź in Poland have evaluated the results of four clinical studies which were carried out between 2016 and 2018, with a total of 3,623 participants. In the process, they have found that the harmful LDL-cholesterol in the persons who were already treated with statins, was decreased in the case of additional intake of Bempedoinsäure to twelve weeks to an average of 18 percent. Nearly 29 percent of the participants achieved the target of less than 70 mg/dl in the control group, which had received a Placebo, it was only 8 percent. Even after 24 and 52 weeks was similar.
Bempedoinsäacid is also without statins effective
Some people do not tolerate statins. This was 614 persons in the case. They had prior to the start of therapy with Bempedoinsäure an average LDL value of 144 mg/dl. This was reduced by the sole administration of Bempedoinsäure to 25 percent, and the effect remained also over the course of a year stable. The researchers expect that the new drug reduces the risk of cardiovascular disease by 11 to 21 percent.
Taking Bempedoinsäure other blood lipid values and inflammatory parameters were positively influenced by. Relatively rare, but there were also side effects, for example, in some cases, to reflect increased uric acid and gout, as well as poorer kidney or liver values. Diabetes was diagnosed under taking Bempedoinsäure rarer new.